10-K: Alpha Cognition Launches ZUNVEYL, Reports Rising Losses

Alpha Cognition Inc. commercially launched its Alzheimer's treatment ZUNVEYL, generating initial revenue, but reported a significant increase in net losses for the fiscal year ended December 31, 2025.

Summary

• Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Alzheimer's disease.
• The company commercially launched ZUNVEYL, an oral tablet formulation for mild-to-moderate Alzheimer's disease, on March 19, 2025, following FDA approval on July 26, 2024.
• ZUNVEYL is positioned as a next-generation acetylcholinesterase inhibitor with expected minimal gastrointestinal side effects and a dual mechanism of action.
• Total revenue for the year ended December 31, 2025, was $10,220,275, a significant increase from $0 in 2024, comprising $6,792,024 from product sales and $3,428,251 from licensing.
• Net loss increased to $(20,669,875) in 2025 from $(14,788,727) in 2024, primarily due to a substantial increase in selling, general, and administrative (SG&A) expenses.
• SG&A expenses surged by 263% to $29,076,123 in 2025 from $8,012,230 in 2024, largely due to commercialization efforts for ZUNVEYL.
• Research and development (R&D) expenses decreased by 52% to $1,867,972 in 2025 from $3,920,412 in 2024, reflecting a shift towards commercialization.
• The company secured a licensing agreement with CMS International Development and Management Limited (CMSI) for ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand, totaling $44 million in potential payments, including a $3 million upfront payment received in January 2025.
• Cash and cash equivalents increased to $66,046,789 as of December 31, 2025, from $48,546,210 in 2024, supported by significant capital raises.
• Capital raises in 2025 included a public offering in October 2025 generating net proceeds of approximately $32.8 million and an over-allotment exercise for $5.25 million. In 2024, a public offering generated net proceeds of approximately $46.15 million.
• The company identified a material weakness in its internal control over financial reporting related to accounting for warrants and stock option liabilities and a lack of segregation of duties, with remediation efforts underway.
• Alpha Cognition is pursuing additional pre-clinical programs, including ZUNVEYL in combination with memantine for moderate-to-severe AD and ALPHA-1062 sublingual formulations for dysphagia and mild traumatic brain injury (mTBI).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed filing. While the commercial launch of ZUNVEYL and initial revenue generation are positive steps, the significant increase in net losses and cash burn, coupled with an identified material weakness in internal controls and ongoing FDA requirements for ZUNVEYL, present considerable challenges and uncertainties for future profitability.

Positives

• Successful FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease on July 26, 2024.
• Official commercial launch of ZUNVEYL on March 19, 2025, marking the company's transition to a commercial stage.
• Generated first-time revenue of $10,220,275 in 2025, including $6,792,024 from product sales and $3,428,251 from licensing.
• Secured a significant licensing agreement with CMSI for ZUNVEYL in Asia, Australia, and New Zealand, with potential payments up to $44 million, including a $3 million upfront payment.
• Successfully raised substantial capital through public offerings in 2024 and 2025, increasing cash and cash equivalents to $66,046,789 by December 31, 2025.
• ZUNVEYL is the second oral therapy for Alzheimer's patients approved in the past decade, offering potential differentiation with minimal GI side effects and a dual mechanism of action.
• Market research indicates high prescriber interest, with 88% of LTC prescribers likely to prescribe ZUNVEYL and a 29% preference share.
• Executed agreements with two of the four major national Pharmacy Benefit Managers (PBMs) for formulary coverage of ZUNVEYL.
• Extended the estimated useful life of a key intangible asset (Memogain License) to February 2044 due to a granted patent application, reducing amortization expense.

Negatives

• Incurred significant net losses, increasing to $(20,669,875) in 2025 from $(14,788,727) in 2024.
• Accumulated deficit grew to $(97,106,775) as of December 31, 2025.
• Cash used in operating activities significantly increased to $(20,380,367) in 2025 from $(7,755,654) in 2024, indicating a higher cash burn rate.
• Selling, general and administrative expenses increased substantially by 263% to $29,076,123 in 2025, primarily due to commercialization efforts.
• The company has a limited operating history and no prior history of commercializing products before 2025, making future viability assessment difficult.
• Reliance on a single Taiwan-based vendor for active pharmaceutical ingredient (API) and a single U.S.-based vendor for ZUNVEYL manufacturing, posing supply chain risks.
• Identified a material weakness in internal control over financial reporting regarding the accounting for warrants and stock option liabilities and a lack of segregation of duties.
• The company believes it was a Passive Foreign Investment Company (PFIC) in 2025 and expects to be in subsequent years, which may have adverse U.S. federal income tax consequences for U.S. investors.
• Certain U.S. patents for ZUNVEYL and ALPHA-0602 are set to expire in 2026, though the company believes other patents are sufficient.
• Did not receive any FDA exclusivity associated with the approval of NDA 218549 for ZUNVEYL.
• FDA required further root cause investigation into high variability of ZUNVEYL dissolution data and development of new dissolution methods and acceptance criteria, with a report due by February 28, 2025.

Risks

• ZUNVEYL oral tablet formulation may fail to achieve broad adoption and commercial success by physicians, patients, hospitals, and healthcare payors.
• Market opportunities for ZUNVEYL may be smaller than anticipated, potentially limiting revenue generation and profitability.
• Reliance on third-party suppliers for manufacturing product candidates, with risks of loss, failure to comply with regulations, or inability to provide sufficient quantities at acceptable quality or prices.
• Exposure to supply chain risks related to manufacturing in Taiwan, including foreign economic downturns and political instability (e.g., China-Taiwan geo-political instability).
• Product candidates have not been manufactured on a commercial scale, and scaling up manufacturing to commercial scale may not be successful, leading to cost overruns or production difficulties.
• Successful commercialization depends on governmental authorities and health insurers establishing adequate coverage, reimbursement levels, and pricing policies; failure to obtain these could limit marketability and revenue.
• Lack of a fully established sales organization, requiring reliance on third parties or building internal capabilities, which may not be effective.
• Significant history of losses and expectation of continued losses for the foreseeable future, with costs potentially increasing substantially.
• Need for substantial additional capital to meet financial obligations and pursue business objectives; inability to raise capital could force delays or elimination of programs.
• Exposure to fluctuations in currency exchange rates, which could adversely affect results of operations.
• Business heavily dependent on the commercial success of ZUNVEYL and the development of future product candidates.
• Risk of not successfully expanding the pipeline of product candidates, impairing business expansion and strategic objectives.
• Substantial delays in preclinical studies and clinical trials, or inability to complete them on expected timelines.
• Use of therapeutic candidates could be associated with side effects, adverse events, or other properties or safety risks, potentially delaying or precluding approval, or limiting commercial profile.
• Interim, top-line, and preliminary data from studies or trials may change as more data becomes available and are subject to audit and verification.
• FDA and comparable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Risk of product liability lawsuits, incurring substantial liabilities and potentially limiting commercialization.
• Identified material weaknesses in internal control over financial reporting, which, if not remediated, could impair ability to produce timely and accurate financial statements.
• Research and development of pharmaceuticals is lengthy, expensive, and inherently risky, with no assurance of regulatory approval for future product candidates.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, global health concerns) could hinder timely development, approval, or commercialization.
• Failure to comply with health and data protection laws and regulations (e.g., HIPAA, CCPA, GDPR) could lead to enforcement actions, penalties, or adverse publicity.
• Regulatory approval in one jurisdiction does not guarantee approval in others, limiting market opportunities.
• Significant competition from large and specialty biotechnology/pharmaceutical companies, academic institutions, and government agencies.
• Challenges to the validity, scope, and enforceability of patents, including those listed in the Orange Book, by third parties.
• Intellectual property litigation could be expensive, time-consuming, and unsuccessful, diverting resources and potentially leading to loss of rights.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation.
• Claims that employees or the company wrongfully used confidential information of former employers or third parties.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Trademarks may be infringed or successfully challenged, harming business.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• ZUNVEYL and future approved products will remain subject to regulatory scrutiny and post-approval requirements.
• Healthcare legislation, including unfavorable pricing regulations or other reform initiatives, may increase difficulty and cost of commercialization.
• Business operations subject to healthcare regulatory laws (e.g., Anti-Kickback Statute, False Claims Act), exposing the company to penalties.
• Need to increase organization size and potential difficulties in managing growth.
• Failure to attract and retain senior management and key scientific personnel.
• Risk of misconduct or improper activities by employees and independent contractors.
• Inability to establish sales or marketing capabilities or enter into third-party agreements.
• Stock price volatility and potential for dilution from future financings.
• Concentration of ownership among existing executive officers, directors, and principal stockholders.
• Sales of substantial numbers of common stock in the public market could cause stock price to fall.
• Ability to use net operating loss carryforwards may be limited.
• No intention to pay dividends.
• Foreign exchange risk associated with Canadian Dollar denominated warrants.
• Unfavorable global economic or political conditions (e.g., Russia-Ukraine, China-Taiwan tensions) could adversely affect business.
• Increased costs and demands from operating as a public company, including Sarbanes-Oxley Act compliance.
• Risks of climate change, natural catastrophic events, and man-made problems.

Future Outlook

The company expects revenue from commercial sales of ZUNVEYL to continue growing year over year as it expands its sales force and implements its sales strategy. It believes it has sufficient capital to achieve operating profitability by 2027, provided it executes its commercial plan in the LTC market and does not advance compounds in the pipeline. The company plans to pursue non-dilutive funding for ALPHA-1062 for Cognitive Impairment with mTBI and is advancing benzgalantamine sublingual formulation as a treatment for mild-to-moderate Alzheimer's disease in 2025, with plans for a comparative pharmacokinetic study and subsequent FDA meeting. It also intends to seek distribution partners for ZUNVEYL in major international territories (Europe, LATAM, Middle East, Asia) and approval for additional indications and product line extensions.

Management Comments

• "The Company believes that it has sufficient capital to achieve operating profitability by 2027, provided the Company executes its commercial plan in LTC market and does not advance compounds in the pipeline."
• "The Company believes that ZUNVEYL is poised to be a next-generation treatment option."
• "The Company believes that we can differentiate ZUNVEYL based on several potential advantages to Alzheimers disease patients."
• "This pricing reflects the companys commitment to ensuring affordability and access while supporting the commercialization strategy in the $2 billion U.S. Alzheimers LTC market."
• "Management is of the opinion that it does have sufficient working capital to fully meet the Companys liabilities and commitments as outlined and planned in the following discussion."
• "Management is of the opinion it will need to raise additional capital to cover upcoming planned Research and Development (R&D), continued commercialization of ZUNVEYL and operating costs."

Industry Context

StockSavvy.ai notes that Alpha Cognition operates in the highly competitive and challenging neurodegenerative disease market, particularly Alzheimer's, which has seen limited drug development success. ZUNVEYL enters a market with existing generic acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and branded options like Adlarity (Corium) and Namzaric (AbbVie). While disease-modifying treatments like Aducanumab (Biogen, discontinued) and lecanemab (Leqembi by Eisai) exist, ZUNVEYL is positioned as a symptomatic treatment, not a direct competitor to DMTs, but rather a potential combination therapy. The high discontinuation rates of current AChEI medications (30% by month 4, 55% by year 1) due to side effects, particularly GI issues, present a significant unmet need that ZUNVEYL aims to address with its expected minimal GI side effects and dual mechanism of action. The company's focus on the long-term care market, which accounts for 36% of AChEI prescriptions, is a strategic move to target a concentrated patient population.

Comparison to Industry Standards

• ZUNVEYL is positioned against established symptomatic treatments for Alzheimer's disease, including Donepezil (Aricept by Eisai and Pfizer), Rivastigmine (Exelon/Exelon Patch by Novartis), Galantamine (Reminyl/Razadyne by Janssen), and Donepezil transdermal system (Adlarity by Corium).
• Unlike these, ZUNVEYL is a patented new innovative product with a dual mechanism of action (enhancing acetylcholine levels and nicotinic receptor sensitivity) and an enteric-coated tablet designed to minimize GI side effects (nausea, vomiting, diarrhea), which are common reasons for discontinuation with existing AChEIs.
• The company highlights that ZUNVEYL's active metabolite binds neuronal nicotinic receptors, notably the alpha-7 subtype, known to positively affect cognition, differentiating it from donepezil and rivastigmine.
• Clinical data published in Neurology (April 2021) supports galantamine's significant risk reduction in severe dementia and strongest effect on cognition, which ZUNVEYL leverages.
• The Wholesale Acquisition Cost (WAC) for ZUNVEYL is set at $820 per month, reflecting a balance between patient access and innovative healthcare solutions in the $2 billion U.S. Alzheimer's LTC market.
• In the TBI market, there are currently no approved acute or chronic treatments, positioning ALPHA-1062IN as a potential first-in-class therapy with an estimated $13.5 billion market size in the U.S. for cognitive impairment with mTBI.
• The company's strategy to combine ZUNVEYL with memantine for moderate-to-severe AD aims to offer differentiating efficacy and tolerability, potentially competing with existing combination therapies like Namzaric (AbbVie).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings nor aware of any contemplated by government agencies.
• The company faces an inherent risk of product liability lawsuits as a result of clinical testing and commercialization.

Related Party Transactions

• Promissory note of $1,400,000 issued to Neurodyn Life Sciences Inc. (NLS) in March 2015 for ALPHA-1062 Technology, which was repaid in 2025.
• Ongoing royalty payments to NLS (1% of revenue over $100 million per annum after Galantos Royalty Payments are met).
• Ongoing royalty payments to Galantos Pharma GmbH (3% of net sales, 10% of sublicensing revenue, 25% of upfront/milestone from sub-licensee) for ALPHA-1062 Technology.
• Ongoing royalty payments to Galantos Consulting (1% of net sales, 2% of sublicensing revenue, 2% of upfront/milestone from sub-licensee) for ALPHA-1062 Technology.
• Loan of $55,000 to Alpha Seven Therapeutics, Inc. (related party through common director/officers) with a provision for credit losses recorded in 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; stock price volatility; adverse impact of PFIC status for U.S. investors; no dividends expected.
• Patients: Access to a new Alzheimer's treatment (ZUNVEYL) with potentially fewer GI side effects; potential for new treatments for moderate-to-severe AD and mTBI in the future.
• Employees: Increased hiring for commercialization and R&D; risk of not attracting/retaining qualified personnel; exposure to misconduct risks.
• Customers (Wholesalers/Pharmacies): New product (ZUNVEYL) to distribute; ongoing negotiations for formulary coverage and reimbursement.
• Suppliers/Contract Manufacturers: Continued reliance on third-party manufacturers, particularly in Taiwan (API) and U.S. (oral tablets), with associated supply chain risks.
• Payors (Medicare/Medicaid, private insurers): Engagement in securing formulary coverage and negotiating agreements for ZUNVEYL; potential for price challenges and cost-containment measures.

Next Steps

• Execute commercialization of the FDA-approved ZUNVEYL oral formulation.
• Pursue new business opportunities for commercial and/or development partners for ZUNVEYL both domestically and internationally.
• Actively engage in securing formulary coverage for ZUNVEYL with U.S. payors and negotiating agreements with pharmacy benefit managers.
• Seek distribution partners for ZUNVEYL in major international territories (Europe, LATAM, Middle East, and Asia).
• Seek approval for potential additional indications and product line extensions for ZUNVEYL.
• Pursue non-dilutive funding sources for ALPHA-1062 for Cognitive Impairment with mTBI.
• Advance benzgalantamine sublingual formulation as a treatment for mild-to-moderate Alzheimer's disease in 2025, including formulation modification and a comparative pharmacokinetic study.
• Meet with FDA to align on the clinical study program required for approval of the sublingual formulation of benzgalantamine.
• Initiate additional pre-clinical toxicity study and manufacturing work for ALPHA-1062 for mTBI to file an IND and potentially enter a Phase 2 trial.
• Continue remediation efforts for the identified material weakness in internal control over financial reporting.
• Conduct further root cause investigation into observed high variability of ZUNVEYL dissolution data and develop new dissolution methods and acceptance criteria, reporting to FDA by February 28, 2025.

Key Dates

Recommendation

Alpha Cognition has achieved a significant milestone with the FDA approval and commercial launch of ZUNVEYL, generating initial revenue and securing a valuable international licensing deal. This marks a crucial transition to a commercial-stage company. However, the substantial increase in net losses and cash burn, coupled with the identified material weakness in internal controls and ongoing FDA requirements for ZUNVEYL's dissolution data, introduce considerable operational and financial uncertainties. While the long-term potential in the Alzheimer's and TBI markets is attractive, the immediate challenges and execution risks warrant a cautious "hold" stance for seasoned investors, awaiting clearer signs of sustained commercial traction, improved financial performance, and successful remediation of internal control issues.

Keywords

Alzheimer's disease, ZUNVEYL, biopharmaceutical, neurodegenerative, FDA approval, commercial launch, drug development, clinical trials, intellectual property, capital raise, SEC filing, 10-K, financial results, corporate governance, risk management, ZUNVEYL oral tablet, ALPHA-1062, mTBI, sublingual formulation, CMSI, licensing, PBMs, acetylcholinesterase inhibitor, financial reporting, internal controls